<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zidovudine and lamivudine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zidovudine and lamivudine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zidovudine and lamivudine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11438" href="/d/html/11438.html" rel="external">see "Zidovudine and lamivudine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12540" href="/d/html/12540.html" rel="external">see "Zidovudine and lamivudine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708844"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Zidovudine, a component of lamivudine/zidovudine tablets, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prolonged use of zidovudine has been associated with symptomatic myopathy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Exacerbations of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, a component of lamivudine/zidovudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue lamivudine/zidovudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis and severe hepatomegaly with steatosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of nucleoside analogues, including lamivudine and zidovudine. Discontinue lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F235239"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Combivir [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868626"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Lamivudine-Zidovudine;</li>
<li>Auro-Lamivudine/Zidovudine;</li>
<li>Combivir;</li>
<li>JAMP-Lamivudine/Zidovudine;</li>
<li>TEVA-Lamivudine/Zidovudine [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F235256"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</li></ul></div>
<div class="block doa drugH1Div" id="F235243"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Because this is a fixed-dose combination product, avoid use in patients requiring dosage reduction.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b> Oral: One tablet (lamivudine 150 mg/zidovudine 300 mg) twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991809"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: Use is not recommended (use dose-adjusted individual components).</p></div>
<div class="block doha drugH1Div" id="F50989085"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is not recommended (use dose-adjusted individual components).</p></div>
<div class="block dop drugH1Div" id="F235249"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12540" href="/d/html/12540.html" rel="external">see "Zidovudine and lamivudine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: Note: </b>Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=10221" target="_blank">https://hivdb.stanford.edu/</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing ≥30 kg: Lamivudine 150 mg and zidovudine 300 mg per tablet: Oral: One tablet twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114952"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents weighing ≥30 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: Use of fixed-dose combination is not recommended; see individual agents.</p></div>
<div class="block dohp drugH1Div" id="F51114953"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents weighing ≥30 kg: Use of fixed-dose combination is not recommended; see individual agents.</p></div>
<div class="block adr drugH1Div" id="F235222"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F3945445"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lamivudine or zidovudine, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Neutrophil count &lt;750/mm<sup>3</sup> or hemoglobin &lt;7.5 g/dL (4.65 mmol/L)</p></div>
<div class="block war drugH1Div" id="F3945446"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: <b>[US Boxed Warning]: Zidovudine is associated with hematologic toxicity, including neutropenia and severe anemia.</b> Use with caution in patients with bone marrow compromise (granulocytes &lt;1,000 cells/mm<sup>3</sup> or hemoglobin &lt;9.5 g/dL).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals.</b> Female gender and obesity may increase the risk for development. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipoatrophy: Zidovudine may cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible; improvement may take months to years after switching to a regimen that does not contain zidovudine. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy: <b>[US Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hepatitis B: <b>[US Boxed Warning]: Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 when therapy is discontinued;</b> monitor patients with clinical and laboratory follow-up for at least several months after treatment discontinuation. Emergence of hepatitis B virus lamivudine-resistant variants has been reported in patients with concurrent HBV infection who received a lamivudine-containing regimen for HIV-1 treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Use with caution in patients with a history of pancreatitis or other significant risk factors for pancreatitis development. Discontinue immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with renal impairment (CrCl &lt;50 mL/minute).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878675"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The major clinical toxicity of lamivudine in pediatric patients is pancreatitis, which occurred in 14% of patients in one open-label, dose-escalation trial; discontinue lamivudine therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. Use with extreme caution and only if there is no satisfactory alternative therapy in pediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis (Epivir prescribing information 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Zidovudine-related adverse hematologic effects may be concentration-dependent and associated with increasing AUC (Fillekes 2014; HHS [pediatric] 2023). Adverse cardiac effects have been associated with zidovudine therapy. A prospective study of 325 pediatric patients aged 7 to 16 years with perinatally acquired HIV evaluated associations between previous or current antiretroviral agents and cardiac echocardiogram measures. When comparing patients currently receiving zidovudine (n=107) with those who were not, zidovudine therapy was associated with increased end-systolic wall stress and slightly larger heart size. Longer duration of zidovudine use was associated with higher wall stress (Williams 2018). A descriptive study evaluated 643 individuals 1 to 25 years of age with perinatally acquired HIV to determine prevalence of early cardiac dysfunction and reported that left ventricular ejection fraction was negatively associated with history of zidovudine exposure. Implications for cardiac outcomes later in life (eg, cardiomyopathy) are unknown (McCrary 2020; Williams 2018).</p></div>
<div class="block foc drugH1Div" id="F235227"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Combivir: Lamivudine 150 mg and zidovudine 300 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Lamivudine 150 mg and zidovudine 300 mg</p></div>
<div class="block geq drugH1Div" id="F235216"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F235233"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (lamiVUDine-Zidovudine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-300 mg (per each): $4.42 - $15.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868627"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Combivir: Lamivudine 150 mg and zidovudine 300 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Lamivudine 150 mg and zidovudine 300 mg</p></div>
<div class="block adm drugH1Div" id="F45854709"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food.</p></div>
<div class="block admp drugH1Div" id="F52614023"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals</p></div>
<div class="block hazard drugH1Div" id="F53101254"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets (NIOSH 2016). Facilities may perform assessment of some (non-antineoplastic) hazardous drugs to determine if appropriate for alternative containment strategies and handling requirements; assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F235229"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>HIV-1 infection, treatment:</b> Treatment of HIV-1 infection in combination with other antiretrovirals.</p></div>
<div class="block mst drugH1Div" id="F235261"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Combivir may be confused with Combivent, Epivir</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">AZT is an error-prone abbreviation (mistaken as azaTHIOprine, aztreonam)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F235250"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F235223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine.  Management: Avoid coadministration of zidovudine-containing antiretroviral therapy with amodiaquine when possible. If combined, monitor closely for neutropenia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine due to the possibility of reduced zidovudine efficacy and increased myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine. Reduced efficacy of zidovudine is possible based on in vitro data. Also, increased myelosuppressive effects are possible with combined administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Oral Inhalation): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Systemic): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sorbitol: May decrease the serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase the serum concentration of LamiVUDine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: Zidovudine may enhance the neutropenic effect of Trimethoprim. Trimethoprim may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52967491"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) Perinatal HIV Guidelines consider this combination an alternative regimen for patients with HIV infection who are not yet pregnant but are trying to conceive (HHS [perinatal] 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F235234"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with zidovudine an alternative NRTI backbone for pregnant patients with HIV infection who are antiretroviral-naive, who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking this combination may continue if viral suppression is effective and the regimen is well tolerated. Although use of this combination has the most experience for use in pregnancy, it has an increased potential for hematologic toxicity and requires twice-daily dosing (HHS [perinatal] 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F235235"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Lamivudine and zidovudine are both present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F3945453"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Amylase, bilirubin, signs and symptoms of pancreatitis. Monitor CBC with differential and platelet count at least every 2 weeks, liver function tests (including signs/symptoms of hepatomegaly), MCV, serum creatinine kinase, viral load, and CD4 count; observe for appearance of opportunistic infections; signs of muscle weakness or pain; blood lactate levels and signs of acidosis</p></div>
<div class="block pha drugH1Div" id="F235219"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The combination of zidovudine and lamivudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance</p></div>
<div class="block phk drugH1Div" id="F235231"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F235236"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo lamivudine zidovudine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">3 tc/azt elea | 3tc complex | Ganvirel duo | Hivirux complex | Imunoxa complex | Kess complex | Lamivudina + Zidovudina dosa | Ultraviral duo | Zetavudin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine Zidovudine alphapharm</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Diavix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Avocomb kid | Lamivudine + zidovudine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Biovir | Far manguinhos lamivudina+zidovudina | Farmanguinhos lamivudina + zidovudina | Furp lamivudina + zidovudina | Lafepe zidovudina + lamivudina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudin Zidovudin Mepha</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Bivek | Lamihope z | Lamivudine and zidovudine | Zidolam</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bivir | Combivir | Lantynon duo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cipladuovir | Combivir | Convudina | Duoviral | Lamivudina + zidovudina | Lamizovir | Lavuzid | Virdual | Zovilam | Zovilam ped</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudin/zidovudin mylan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudin/Zidovudin beta | Lamivudin/Zidovudin Heumann | Lamivudin/zidovudin hormosan | Lamivudin/zidovudin puren | Lamivudine and zidovudine | Lamivudine/zidovudine teva | Lamizido</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Dunox | Zidofin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Duvirox | Zidomax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lamizidine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudina/zidovudina accord | Lamivudina/Zidovudina Aurobindo | Lamivudina/Zidovudina Mylan | Lamivudina/Zidovudina teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lamivudine &amp; zidovudine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine zidovudine Zentiva | Lamivudine/zidovudine arrow | Lamivudine/zidovudine cristers | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine | Lamivudine/Zidovudine Sandoz</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Bivek</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine teva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine teva | Lazid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Duviral</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Cytocom | Duovir | Lamda-z | Lamuzid | Lazid | Virocomb | Zidolam | Zidovex l | Zovilam</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aspen lamzid | Avocomb | Avocomb kid | Combivir | Duovir | Lamivudine &amp; zidovudine | Lamivudine and zidovudine | Lamivudine/zidovudine | Lamozid | Lazid | Lazidariv | Zidolam</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Condine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine / zidovudine teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/Zidovudine Sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/Zidovudine Sandoz</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Altair pro | Cirilen | Combivir | Duzibindo | Envamonte | Isismer | Lazibanv | Mivutev | Omidum | Pinoremna | Vicrate | Zilamtec</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Arrow lz | Combivir | Hovid lambivir | Lamizido | Zovilam</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine &amp; zidovudine | Lamivudine and zidovudine | Lamivudine/zidovudine | Lamzidan | Lazid | Zidolam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine mylan | Lamivudine/Zidovudine Sandoz | Lamivudine/zidovudine teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Ganvirel duo | Lamivudina + zidovudina | Lamivudina y zidovudina | Perdolat | Zidolam</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lodiz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamiwudyna/zydowudyna mylan | Lazivir</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine and zidovudine | Lamivudine/zidovudine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudina + zidovudina accord | Lamivudina + Zidovudina Aurobindo | Lamivudina + Zidovudina Farmoz | Lamivudina + Zidovudina Generis | Lamivudina + Zidovudina Mylan | Lamivudina + zidovudina sandoz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Duovir | Lamivudina zidovudina | Lamivudina zidovudina nl pharma | Muvidina | Zetavudin | Zidovudir</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudina/Zidovudina Mylan | Lamivudine/zidovudine teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Dizaverox | Emlazid | Lami-zidox | Lazevun | Virocomb | Zidolam | Zidovudine lamivudine | Zidovudine+lamivudine | Zidovudine+lamivudine vial | Zilacomb | Zilam tl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Lamivudine/zidovudine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Combid | Zilarvir | Zovilam</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Lamivudine/zidovudine mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Duovir | Lamivudine zidovudine sandoz | Zidolam | Zovilam</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lamivudine and zidovudine | Lamivudine and zidovudine macleods | Lamivudine/zidovudine | Lamivudine/zidovudine matrix | Lamivudine/zidovudine mylan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Combivudine | Lamihop 3 | Lamivudine/zidovudine | Lasivudine | Lazid | Zidolam</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Duovir | Lamivudine + zidovudine | Lamozid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Combivir | Kess complex | Lamivudina / Zidovudina ion | Lamivudina Compuesta | Muvidina | Zetavudin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Combivir</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen lamzid | Auro lamizido | Avocomb | Cipla duovir | Colamziv | Combivir | Combozil | Divuwin | Duovir | Macleods Lamivudine/Zidovudine | Sonke Zidovudine+Lamivudine | Zovilam</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aspen lamzid | Avocomb | Bivir | Combivir | Duovir | Lamivudine + zidovudine | Lamivudine 150mg + zidovudine 300mg | Lamivudine/zidovudine | Varivar | Zidolam | Zidovex l</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Avocomb | Combivir | Lamivudine + zidovudine | Lamivudine and zidovudine | Varivar | Zovilam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference">
                  Combivir (lamivudine/zidovudine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Combivir.2">
<a name="Combivir.2"></a>Combivir (lamivudine/zidovudine) [product monograph]. Montreal, Quebec, Canada: ViiV Healthcare ULC; May 2023.</div>
</li>
<li>
<div class="reference">
                  Epivir (lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736440">
<a name="24736440"></a>Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. <i>Pediatr Infect Dis J</i>. 2014;33(5):495-498. doi:10.1097/INF.0000000000000143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-and-lamivudine-drug-information/abstract-text/24736440/pubmed" id="24736440" target="_blank">24736440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-and-lamivudine-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794518">
<a name="31794518"></a>McCrary AW, Nyandiko WM, Ellis AM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. <i>AIDS</i>. 2020;34(4):539-548. doi:10.1097/QAD.0000000000002445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-and-lamivudine-drug-information/abstract-text/31794518/pubmed" id="31794518" target="_blank">31794518</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention CDC); National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed May 1, 2019.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>. Updated January 31, 2023. Accessed March 2, 2023.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated December 30, 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30102660">
<a name="30102660"></a>Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. <i>AIDS</i>. 2018;32(16):2337-2346. doi:10.1097/QAD.0000000000001988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zidovudine-and-lamivudine-drug-information/abstract-text/30102660/pubmed" id="30102660" target="_blank">30102660</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10221 Version 300.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
